Files
Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/218050
The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used.
Subject (English)
Citation
Citation
RODRIGUEZ-TAJES, Sergio, et al. The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis. Liver International. 2023. Vol. 44, num. 2, pags. 279-285. ISSN 1478-3223. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/218050